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ttp://dx.doi.org/10.1016/j.jmoldx.2013.09.004Fragile X syndrome and associated disorders are characterized by the number of CGG repeats and
methylation status of the FMR1 gene for which Southern blot (SB) historically has been required for
analysis. This study describes a simple PCR-only workﬂow (mPCR) to replace SB analysis, that
incorporates novel procedural controls, treatment of the DNA in separate control and methylation-
sensitive restriction endonuclease reactions, ampliﬁcation with labeled primers, and two-color ampli-
con sizing by capillary electrophoresis. mPCR was evaluated in two independent laboratories with 76
residual clinical samples that represented typical and challenging fragile X alleles in both males and
females. mPCR enabled superior size resolution and analytical sensitivity for size and methylation
mosaicism compared to SB. Full mutation mosaicism was detected down to 1% in a background of 99%
normal allele with 50- to 100-fold less DNA than required for SB. A low level of full mutation mosaicism
in one sample was detected using mPCR but not observed using SB. Overall, the sensitivity for detection
of full mutation alleles was 100% (95% CI: 89%e100%) with an accuracy of 99% (95% CI: 93%e
100%). mPCR analysis of DNA from individuals with Klinefelter and Turner syndromes, and DNA from
sperm and blood, were consistent with SB. As such, mPCR enables accurate, sensitive, and standardized
methods of FMR1 analysis that can harmonize results across different laboratories. (J Mol Diagn 2014,
16: 23e31; http://dx.doi.org/10.1016/j.jmoldx.2013.09.004)Supported by National Institute of Child Health & Human Development
grant R44 HD060450-02 (S.F.-S., R.C., G.J.L., and A.G.H.) and by Gal-
liera Genetic BankeItalian Telethon grant (project no. GTB12001, to M.G.,
E.G., and D.A.C.).
M.G. and E.M.J.B. contributed equally to this work.
Disclosures: S.F.-S., R.C., G.J.L., and A.G.H. are employees of Asuragen,
which manufactures the AmplideX reagents used in this study.Diverse developmental, mental, and reproductive disorders
are associated with both the number of cytosine-guanine-
guanine (CGG) repeats and the methylation status of the
fragile X mental retardation-1 (FMR1, NM_002024.4)
gene.1e3 Excessive CGG repeat expansion is directly linked
with hypermethylation of the gene through an epigenetic
mechanism that is distinct from X chromosome inactivation
and developmentally timed after lyonization.4 Because the
FMR1 protein (FMRP) is a master regulator of genes
involved in synaptic plasticity,5 the intellectual and behav-
ioral consequences of quantitative FMR1 silencing are
profound. Methylation of full mutation expansions (>200
CGG), however, can be incomplete, and less severe phe-
notypes may be associated with methylation mosaicism.6e8
In premutation alleles (55 to 200 CGG) the number of CGGstigative Pathology
.can inﬂuence the risks and phenotype of fragile
Xeassociated tremor/ataxia syndrome (FXTAS, OMIM
300623),9 fragile Xeassociated primary ovarian insufﬁ-
ciency (FXPOI, OMIM 300624),10,11 and autism spectrum
disorders.12,13 Methylation status or X-inactivation in
females may further inﬂuence the risk and phenotype of
these conditions even if the results reported are still incon-
clusive.10,11,14 These premutation alleles are relatively
Grasso et alcommon in the general population, occurring in 1 in 130 to
250 women and in 1 in 250 to 810 men, as reported in the
United States,15,16 suggesting a broader need for FMR1
characterization in the general population. Differences in
methylation status have also been reported between DNA
from whole blood compared to skin ﬁbroblasts, which may
be closer in cellular origin to brain and more reﬂective of
phenotype.17 Thus, it is critical to accurately and reliably
assess the CGG repeat length and spectrum of methylation
characteristics in individuals with FMR1 premutation and
full mutation expansions, and to enable analysis of alter-
native sample types rather than peripheral blood.
Southern blot (SB) analysis is currently the gold standard
method for determining size and methylation status in
expanded FMR1 alleles. However, this procedure is severely
limited by the amount of genomic DNA material that is
required, a tedious workﬂow, and variable sensitivity. Dis-
advantages of SB include low resolution and the inability to
accurately size premutation and normal alleles. Therefore,
most clinical laboratories currently rely on a combination of
PCR and SB analysis because of the technical limitations and
the speciﬁc pitfalls of each method that, if used alone, could
induce potential misinterpretation of the genotype.18,19
Various alternatives to SB analysis have been reported that
use bisulﬁte or enzymatic pretreatment ofDNAbefore PCR to
obtain methylation status.20e25 These methods have been
typically restricted to the analysis of male samples because
of the inefﬁciency of PCR or confounding presence of two
X chromosomes in females.24,25 Alternative methylation
markers have been proposed but lack direct association with
the number ofCGG repeats.26Concurrent assessment ofCGG
repeat length and of allele-speciﬁc methylation status in both
males and females has been demonstrated.23 Thismethylation
PCR (mPCR) method was based on the analysis of DNA
treated with methylation-sensitive endonucleases before
FMR1 gene-speciﬁc PCR.27 The resultswere concordant with
SB analysis across a range of genotypes.However, a reference
controlwas incorporated that overlappedwith samples having
alleles of 38 to 42 CGG, and the approach lacked additional
controls that would beneﬁt routine testing in a clinical labo-
ratory environment.
Herein, we report the inclusion of novel procedural controls
and a simpliﬁed workﬂow for mPCR that advance FMR1
analysis without the need for SB analysis. We compare results
betweenmethods using a range of challenging clinical samples
obtained from two European laboratories. We demonstrate
concordance and improved detection of methylation and size
mosaicism relative to SB analysis. The ability to analyze novel
sample types and samples with aneuploidy that might be
encountered during standard fragile X testing is presented.
Consequently, this report provides the ﬁrst interlaboratory
validation of a PCR-based FMR1 assay that can accurately
assess repeat length and methylation status in both males and
females (including all premutation and full mutation alleles),
and thus support routine fragile X testing without the
requirement for SB analysis.24Materials and Methods
Sample Cohort and Characterization
Residual DNA samples, previously tested for fragile
X status at either the Laboratory of Human Genetics, Gal-
liera Hospital in Genoa, Italy (GH), or the Laboratory for
Diagnostic Genome Analysis of the Department of Clinical
Genetics at the Leiden University Medical Center (LUMC)
in the Netherlands, were selected for analysis. Genomic
DNA was isolated at respective sites from peripheral blood
using their standard methods. The 42 samples from the GH
comprised 30 females and 12 males representing 7 normal,
1 intermediate, 9 premutation, 17 full mutation, and 5 full
mutation mosaics (with pre- and full mutation alleles). This
cohort also included a sample with a chromosome Xq27.3/
q28 deletion, Klinefelter syndrome (47,XXY), and Turner
syndrome (45,X). Matched DNA samples isolated from
blood and sperm were analyzed. Residual DNA samples
from LUMC comprised 8 males and 26 females represent-
ing 6 normal (including 3 homozygous females), 4 inter-
mediate, 13 premutations, and 11 full mutations. Each
laboratory performed testing on their laboratory’s DNA
samples. PCR analysis for repeat length (repeat primed
PCR) was done using AmplideX FMR1 PCR reagents
(Asuragen, Austin, TX)28,29 or an alternate method30 as
indicated. SB analysis was based on EcoRI/EagI digestion
at GH and HindIII/EagI digestion at LUMC according to
previously published methods.1,31Cell-Line DNA Samples, Controls, and Methylation
Standards
Cell-line DNA samples and controls were obtained from
Asuragen or the NIGMS Human Genetic Cell Repository at
the Coriell Institute for Medical Research (Coriell Institute,
Camden, NJ). A summary of the samples used in this study,
listed according to the source and the range of CGG repeats
are provided in Table 1. Two cell-line DNA samples were
mixed to form a 20% 940 CGG sensitivity control using 16
ng/mL NA06895 (23 CGG) and 4 ng/mL NA09237
(approximately 940 CGG). Four cell-line DNA samples were
mixed to formulate a six-allele process control representing
alleles for 20, 29, 31, 54, 120, and approximately 199
CGG.27 An additional pooled cell-line control, AmplideX
process control (Asuragen), was used to generate peaks
corresponding to 18, 30, 32, 56, 85, 116, and >200 CGG
from a single PCR. The CGG repeat lengths for alleles up to
120 CGG were veriﬁed using DNA sequencing and used to
calibrate CGG repeat length sizing on different capillary
electrophoresis (CE) platforms. Full mutation methylation
standards were formulated as a mixture of gene-speciﬁc PCR
products of NA04025 (645 CGG)27 that were methylated
using HpaII methyltransferase (New England Biolabs, Ips-
wich, MA) and mixed with unmethylated amplicons at
approximately 6000 copies/mL in a background of 5 ng/mLjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Summary of the Control Samples and Cell Lines Used in this Study, Listed According to the Source and the Range of CGG Repeats
Component Coriell cat# CGG repeats Used in the study
Process control NA20239 20, 199 Pooled mixture of cell lines used to calibrate repeat sizing
between instruments and laboratoriesNA07541 29, 31
NA20230 54
NA06891 120
20% 940 NA06895 23 Mock mosaic sample used for assessment of instrument sensitivity
NA09237 >200
Methylation standards NA06905 23, 78 Carrier DNA background for methylation standards
NA04025 >200 (645 CGG) PCR products from this cell line were treated with HpaII
methyltransferase and blended to create methylation standards
Digestion and reference controls DigCtrl w212 bp (“6 CGG”) Plasmid DNA spiked into each sample to be detected in FAM but
decreased in HEX
RefCtrl w230 bp (“0 CGG”) Plasmid DNA spiked into each sample
AmplideX process control 45913 18, 30, 32, 56, 85,
1, 16, and >200
Prepooled cell-line mixture generating alleles used for instrument
repeat sizing correction and as a routine batch control
FMR1 Analysis without Southern BlotNA06905. These standards comprised alleles at 23 and 78
CGG and amplicons >200 CGG at different mass ratios of
methylated and unmethylated DNA. Expected results for
methylation standards at 0%, 50%, and 100% methylation
were successfully obtained at both laboratories before clin-
ical sample testing.
FMR1 mPCR Assay
DNA samples were analyzed for methylation status and
CGG repeat length using the AmplideX FMR1 mPCR re-
agents (Asuragen) according to the manufacturer’s recom-
mended protocol. An overview of the workﬂow, a
representative schematic of the effect of digestion with
HpaII, and an example data proﬁle for the AmplideX pro-
cess control are shown in Figure 1. Brieﬂy, 8 mL of 10 to 30
ng/mL DNA samples were premixed with two plasmids: a
digestion control (DigCtrl) and PCR reference control
(RefCtrl). This premixture was separately aliquoted to a
control or methylation-sensitive digestion reaction. Re-
striction digestion, PCR, and capillary electrophoresis were
performed as previously described.23 All alleles were
detected using FAM-labeled primers, but only the propor-
tion of the protected methylated allele was available for
PCR using HEX-labeled primers (Figure 1B). Lack of
methylation at either HpaII site resulted in digestion and
thus no ampliﬁcation.
Data Analysis
Electropherograms were analyzed using GeneMapper
version 4.1 (Life Technologies, Carlsbad, CA). The DigCtrl
was formulated with unmethylated HpaII sites and yielded
PCR products detected at 212 bp. PCR products from the
RefCtrl were detected at 230 bp. Both amplicons were
outside the range of a minimally sized FMR1 allele (233 bp
or 1 CGG) and did not interfere with sample detection
(Figure 1C). Omission of HpaII in the digestion reaction
was observed as a high signal in the HEX channel for the
DigCtrl, and consequent lack of digestion and higherThe Journal of Molecular Diagnostics - jmd.amjpathol.orgpercent methylation for unmethylated alleles. Samples were
analyzed when the ratio of HEX to FAM in the DigCtrl was
<0.15 (>85% digested) and the ratio of HEX to FAM peak
heights for the RefCtrl amplicons were between 0.5 and 3.
The CGG repeat length was derived for alleles up to 200
CGG using a linear ﬁt to the process control amplicons
versus size in bp. Full mutation alleles were identiﬁed
as >200 CGG. The percent methylation for each peak,
%Mei,height, was calculated as the normalized ratio of peak
heights in the HEX channel to FAM channel for each allele
amplicon according to the equation:
%Mei;heightZ100

Peaki=RefCtrl

HEX
Peaki=RefCtrl

FAM
ð1Þ
where Peaki corresponds to the height of each allele amplicon
peak and RefCtrl corresponds to the height of the reference
control peak in each color. Methylation percentages >100%
were reported as 100%. The percent activation on an allele was
calculated as 1  %Me.
Results
This study was structured to assess mPCR in two inde-
pendent laboratories with respect to: i) analytical sensitivity
and detection of low-abundance full mutation mosaicism; ii)
concordance with SB analysis; and iii) methylation assess-
ment of novel sample types.
Analytical Sensitivity and Detection of Size and
Methylation Mosaicism
The sensitivity of the method was evaluated over a range
of DNA inputs and for detection of low-abundance full
mutation mosaicism. In a titration of a mosaic full mutation
allele, as little as 1% of a mass fraction of a 645 CGG
allele in the background of a 23 CGG allele was observ-
ed (Figure 2). Thus, 800 pg (242 haploid copies) of a full25
Grasso et almutation allele could be detected in a total of 80 ng of DNA.
mPCR analysis of 20 to 320 ng (2.5 to 40 ng/mL) DNA from
males and females was also assessed. The signal intensity of
full mutation alleles was similar above 20 ng (10 ng each for
the HEX and FAM PCRs) without a signiﬁcant change in
percent methylation. The optimal range for mPCR was 40 to
160 ng of input DNA, which was still approximately 50- to
100-fold less than required for SB analysis. For normal al-
leles at or above 40 ng, the signal was generally saturating
or >6000 relative ﬂuorescence units (Supplemental
Figure S1). In these cases, methylation status of the
normal allele was either obtained from a second CE injec-
tion of 2 kV for 10 seconds or listed as not determined.A 
C
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26mPCR and SB Analysis of Representative Clinical
Samples
A set of 76 clinical samples, including different sources of
DNA and individuals with X chromosome aneuploidies,
was analyzed using mPCR and SB. These samples high-
lighted important distinctions between mPCR and SB
analysis with regard to sensitivity, resolution, and data
formats. Representative comparisons for eight samples, ar-
ranged according to full mutation type and sex, are shown in
Figure 3.
A fully methylated full mutation allele in a male sample
with an estimated 400 to 660 CGG repeats by SB analysis
was detected as >200 CGG and 100% methylation using
mPCR (Figure 3A). Similarly, a male full mutation sample
with premutation mosaicism was detected with approxi-
mately 5% methylation of a 164 CGG mosaic allele
consistent with the weaker premutation-sized band detected
using SB (Figure 3B). In DNA from females, both the
normal and full mutation alleles were easily detected using
mPCR along with assessment of the normal allele methyl-
ation status. An example of highly skewed activation on the
normal allele (11% methylation) and methylation on the full
mutation allele (100%) was observed (Figure 3C). This
result was consistent with an absence of the 5.2 kb band on
the SB and the methylated band in the full mutation region.
In comparison, a female sample was detected with 53%
methylation of the normal allele, indicating random X-
inactivation, whereas the full mutation allele from this
sample showed 100% methylation, consistent with SB
analysis (Figure 3D). Consequently, mPCR provided very
similar data for full mutation alleles as SB analysis.
Female premutation alleles were often characterized by
two distinct distributions of size and methylation statesFigure 1 A: Methylation PCR (mPCR) workﬂow. DNA samples were
prepared for methylation assessment by mixing with procedural controls
and treating with separate methylation-sensitive restriction and control
reactions followed by PCR using different dye labels. The HEX- and FAM-
labeled amplicons were pooled and sized using capillary electrophoresis.
B: Schematic representation of the amplicon region and outcomes of
digestion and PCR. The PCR primers spanned two HpaII restriction sites 95
bp from the beginning and another 45 bp from the end of the repeat region
using a forward (F) primer and either a FAM- or HEX-labeled reverse primer:
R-FAM or R-HEX, respectively. Products from the control digestion were
intact and ampliﬁed using FAM-labeled primers, but after digestion with
HpaII, only alleles fully methylated at both sites were ampliﬁed using HEX-
labeled primers. Lack of methylation at either site resulted in no ampliﬁ-
cation. C: Example of two-color data proﬁles for a multi-allele control.
Electropherograms in the FAM channel yielded the total FMR1 proﬁle for
that sample and determination of CGG repeats. The signal intensity in the
HEX channel corresponded to the methylated component of that allele
amplicon. The percent methylation was determined using the ratio of peak
heights for each in both channels (equation) normalized to the peak height
of the reference control (RefCtrl), one of the plasmid DNA controls spiked
into each PCR. Reduction of signal in the HEX channel for the digestion
control (DigCtrl), another plasmid DNA spiked into each reaction, corre-
lated with activity of HpaII with expected reduction of signal in the HEX
channel. gDNA, genomic DNA; UTR, untranslated region.
jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 2 Methylation PCR (mPCR) sensitivity
for the detection of a full mutation mosaic allele.
Peak proﬁles for a titration of NA04025 (male full
mutation, 645 CGG) mixed into a background of
NA06895 (normal male, 23 CGG) show detection to
as low as 1% mass fraction of the 645-CGG allele in
the background of a 99% mass fraction of a normal
sample (800 pg of a full mutation allele in a total
of 80 ng of DNA mixture).
FMR1 Analysis without Southern Blot(Figure 4). In contrast to a single distribution of peaks with a
uniform change in methylation (Figure 4A), many pre-
mutation alleles had a set of fully methylated peaks of one
size distribution followed by unmethylated peaks of longer
size distribution (Figure 4, B and C). This level of mosai-
cism, observed in 14 of 22 females, was unresolved using
SB analysis. For example, mPCR analysis yielded repeat
lengths of 91 and 112 CGG that were mostly methylated
and peaks centered at 118 CGG that were unmethylated
(Figure 3E). SB analysis of DNA from another female
revealed only a fully methylated premutation band, because
of skewed X-inactivation, whereas the mPCR revealed also
the presence of an unmethylated expansion >200 CGG
(4%) undetectable by SB (Figure 3F). Therefore, when
comparing to SB, partial methylation was estimated as the
methylation from several representative peaks in the elec-
tropherogram. This effect could be subtle. The unmethylated
region of the premutation allele could have very low signal
intensity (Supplemental Figure S2) or be indistinct by SB
analysis because low sizing resolution for premutation al-
leles. Thus, mPCR provided superior analysis of CGG size
and methylation mosaicism in these apparently more com-
plex female premutation alleles.
mPCR analysis of matched blood and sperm DNA, and
samples with other karyotypes also yielded results consis-
tent with SB analysis. DNA from an unmethylated full
mutation male, observed as a smear <5.2 kb by SB, was
detected as a broad range of lower signal unmethylated
peaks using mPCR (Figure 3G). These peaks were separated
by 3 bp each and extended into the full mutation range of
>200 CGG. Repeat analysis of this sample yielded the same
result, and neither the control DNA nor other clinical DNA
samples with a full mutation allele manifested this peakThe Journal of Molecular Diagnostics - jmd.amjpathol.orgpattern. A sample of DNA isolated from sperm from the
same patient was detected with an unmethylated pre-
mutation centered at 99 CGG in concordance with the
unmethylated band detected using SB (Figure 3H). Even
though the methylation proﬁles were similar between
methods, acquisition of the mPCR proﬁles required sub-
stantially less DNA than SB analysis required.
Samples with X chromosome aneuploidies could be
ﬂagged for further testing using mPCR. A female sample
with a chromosome del(X)(q27.3q28) deletion was detected
as a single, completely unmethylated peak of 37 CGG using
mPCR. Similarly, a female sample with Turner syndrome,
45,X, was detected as an unmethylated, single-peak allele of
29 CGG (Supplemental Figure S3A). Apparent homozy-
gosity of the 29 CGG allele was excluded because an
unmethylated peak would be inconsistent with the proﬁle of
a normal homozygous female. These results were consistent
with SB analysis and distinct from other female homozy-
gous samples in our study. Analysis of a male sample with
Klinefelter syndrome, 47,XXY, was observed as a fully
methylated full mutation allele and a fully methylated 29
CGG allele of high signal intensity (Supplemental
Figure S3B). Critically, the presence of the normal allele
did not confound detection of a full mutation allele in the
same male sample and yielded an mPCR proﬁle distinct
from methylation mosaicism.
Concordance Assessment between mPCR and
SB Analysis
Results of SB analysis, repeat length, and percent methyl-
ation using mPCR for 76 clinical samples are listed in
Supplemental Table S1. mPCR results were categorically27
Figure 3 Methylation PCR (mPCR) electropherograms and Southern blot images for male full mutation (FM), female FM, female premutation (PM), and
mosaic samples and matched sources of DNA. Male, fully methylated full mutation allele (A); male with FM/PM mosaicism (B); female, FM with skewed X-
inactivation (C); female, FM with random X-inactivation (D); female, PM with speciﬁc pattern of size and methylation mosaicism obscured using SB, with
arrows highlighting difference in size and methylation states for the larger allele (inset) (E); female sample showing higher resolution and sensitivity of
detection for a FM allele not detected using SB (F); matched blood (G); and sperm sample for a male with full mutation allele in the blood but premutation in
the sperm (H). SB images include a normal female sample illustrating 2.8 and 5.2 kb bands, respectively.
Grasso et alconcordant to SB analysis for 75 of 76 samples. In one case
(GH-FX549), an unmethylated full mutation allele was
detected using mPCR in a female sample previously iden-
tiﬁed with only a large fully methylated premutation allele
(Figure 3F). Thus, if considering SB as the reference
method, mPCR had a sensitivity of 100% [95% conﬁdence
interval (CI): 89%e100%] and speciﬁcity of 99% (95% CI:
93%e100%) for full mutation allele detection. For control
DNA tested at both sites, the sensitivity and speciﬁcity were
100%. The activation ratio, calculated as the unmethylated
ratio on the normal allele for four normal females was 0.47
compared to 0.70 for 11 female full mutation samples. Of
the 33 full mutation samples in our study that were fully
methylated by SB, 29 had methylation percentages by
mPCR detected as >90%. Two samples were detected with
88% and 79% methylation, respectively, and another with
full mutation peaks ranging from 87% to 100% methylation.
In another sample (GH-FX630/10ddata not shown), mPCR
yielded 47% methylation on a full mutation allele indicated
as fully methylated using SB analysis; however, the SB had
low-intensity bands not allowing partial methylation of
this allele to be ruled out. The additional ﬁndings in the
clinical samples (eg, unmethylated or partially methylated
full mutations) were considered components of a complex28genotype. Differences in detection reﬂected the higher
sensitivity of mPCR than SB analysis.
Discussion
The growth in referrals for fragile X testing and recent ad-
vances in therapies for fragile X syndrome place a higher
demand on the throughput, efﬁciency, and interlaboratory
accuracy of fragileX testing. Themolecular analysis ofFMR1
has always been quite time consuming and low throughput
because of the reliance on a combination of PCR and SB.
Moreover, multiple procedural variants of SB analysis can
inﬂuence its sensitivity and may result in miscalls of full
mutation status.32 Recent advances in targeted therapies for
fragile X have shown a predictive response based on the de-
gree of FMR1 methylation. Improvements in hallmark
symptoms of fragile X syndrome were observed for in-
dividuals with a fully methylated full mutation allele but not
for those with mosaicism.33 This link between response to
therapy and accurate assessment of methylation makes reli-
able and sensitive detection of these features paramount.
In this study, a previously published methylation PCR
method,23 improved with the incorporation of novel pro-
cedural controls and a modiﬁed workﬂow for routine FMR1jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 4 Examples of size and methylation mosaic patterns in female
premutation alleles detected using methylation PCR (mPCR). A and B: An
example proﬁle, LUMC14 (A), wherein the entire premutation allele is
partially methylated compared to B, a proﬁle in which the premutation
allele is split into a group of fully methylated peaks and a group of
unmethylated peaks. C: A similar proﬁle highlighting size and methylation
mosaicism in these alleles.
FMR1 Analysis without Southern Blotwas assessed. This mPCR method was validated by two
independent European laboratories using a range of chal-
lenging clinical samples. mPCR enabled superior size res-
olution and analytical sensitivity for size and methylationCGG exp. up to 200
(Premutation range)
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Figure 5 Proposed PCR-only workﬂow for routine FMR1 analysis in males (A)
traditional workﬂow at Genoa Hospital. All samples >200 CGG can be reﬂexed to m
alleles). Male samples with premutation-range alleles can be assessed with mPCR b
ﬁrst-step approach with females would yield expanded alleles>200 CGG for mPCR an
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The Journal of Molecular Diagnostics - jmd.amjpathol.orgmosaicism compared to SB, while providing nearly perfect
categorical concordance across 76 residual clinical samples.
The observed shift in activation ratio for female full mutation
alleles, even though limited in number, was consistent with
data from SB analysis and previously published results.23,34
Furthermore, highly skewed activation of the X chromo-
some harboring a premutation allele was resolved using
mPCR for all samples in our study (Supplemental Table S1).
Our approach represents a fundamental improvement
over the workﬂow and reagents required for SB analysis. In
our laboratories, the total time for SB analysis was a mini-
mum of 4.5 days, with 1.5 days for digestion and agarose
gel, 2 days for overnight SB, labeling, and overnight hy-
bridization followed by washing, and 1 day for ﬁlm expo-
sure. This process required maintenance and disposal of
different stock solutions, buffers, and radiolabeled probes.
By contrast, the digestion and PCR steps of mPCR could be
completed within 6 hours using an overnight run on the CE
for complete analysis of 48 to 96 samples within 24 hours.
Only eight reagent vials for digestion and PCR, and a ROX-
labeled ladder were required, without a need for radioactive
or chemiluminescent probes. The incorporation of novel
controls helped improve reliability relative to SB analysis. A
mixture of cell-line DNA samples representing different
CGG repeats and methylation states, similar to the control
shown in Figure 1C, were tested as a single-well batch
control (data not shown). The reference control provided an
indication and internal normalizer for efﬁciency between the
HEX- and FAM-labeled PCRs. The digestion control pro-
vided an internal quality metric of digestion efﬁciency for
each sample. Although SB can be used to estimate the size
of full mutation alleles, we elected to report these as >2001 Normal + Full Mut.
(expanded >200 CGG)
2 Alleles
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ormal homozygosity, ﬂagging the sample for further analyses. aCGH, array
pliﬁcation; RP-PCR, repeat primed PCR (AmplideX FMR1 PCR).
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Grasso et alCGG, which was the sizing resolution limit of CE analysis.
This approach is consistent with sizing inaccuracy of SB35
and the understanding that the methylation status, and not
the magnitude of CGG repeats, is associated with pheno-
type.2 However, a simple agarose gel of the FAM-labeled
PCR products can be used to obtain sizing of full
mutation alleles,27 and we have begun to explore semi-
automated or precast gel systems to enable this approach.
The 50- to 100-fold reduced DNA input required by
mPCR compared to SB can enable the analysis of alterna-
tive clinical specimens than peripheral blood with potential
beneﬁts for sample procurement, sample management, and/
or phenotype association studies. For example, the ratio of
full mutation to premutation alleles in skin ﬁbroblasts,
which are ectodermal and closer to brain cells in origin,
might be a better indicator of psychological impairment than
the ratio in blood cells.17,36 Collection of DNA from alter-
native sources such as saliva or buccal swabs can also
reduce the costs, storage, and shipping burdens associated
with whole-blood DNA. Because fear of phlebotomy can be
the most signiﬁcant reason for refusing to participate in a
clinical research study,37 the ability to obtain alternative
samples for fragile X testing may encourage broader
participation in important research studies.
Incorporation of mPCR suggests standardization of fragile
X testing schemeswithout the need for SB analysis (Figure 5).
In this proposed scheme, all samples would be tested for
repeat size using repeat primed PCR. mPCR would be per-
formed on all males and females with an expanded allele
>200 CGG. For males, mPCR analysis could be performed
on all premutation samples, the approach taken at LUMC, or
be dependent on the indication of intellectual disability
(Figure 4A), the approach taken at the GH. For females with
larger premutation alleles, mPCR could be used to better
deﬁne the correct allele category based on size and degree of
methylation. For example, in sample GH_FX 227, peaks
corresponding to 32, 187, and >200 were detected by repeat
primed PCR and mPCR (Supplemental Table S1), but only
normal and approximately 200 were detected by SB. This
distinction in size and methylation status, due to better size
resolution of mPCR, may help reﬁne classiﬁcation or identify
particular endophenotypes in females with these alleles.
DNA from females indicated to be homozygous for a
speciﬁc FMR1 repeat could also be analyzed for potential
X-chromosome abnormalities (Figure 5B). Considering that
an increasing number of females undergoing FMR1 testing
are referred from infertility centers, mPCR may help iden-
tify particular features of premutation alleles or X chromo-
some abnormalities that might underlie the infertility. At the
GH, 2 of 76 females (without intellectual disability and
showing only one allele by repeat primed PCR) were found
to have either an Xq deletion encompassing the FMR1 gene
or Turner syndrome. Indeed, the sizing accuracy of mPCR
compared to SB could provide tools to better understand the
cutoff of full mutation allele sizes and links to phenotypes
based on differences in methylation for alleles spanning the30genotype range. Thus, mPCR represents an important
technical advance in fragile X testing that can eliminate the
need for SB analysis and meet growing demands for accu-
rate characterization of the FMR1 gene.
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